Iron­wood to buy Vec­tivBio in $1B all-cash deal to ex­pand rare gas­troin­testi­nal pipeline 

Iron­wood Phar­ma­ceu­ti­cals agreed to buy Swiss biotech Vec­tivBio in an all-cash deal with an es­ti­mat­ed ag­gre­gate con­sid­er­a­tion of about $1 bil­lion, ex­tend­ing the “blis­ter­ing” M&A pace of 2023’s first half.

The Boston drug­mak­er will buy the Eu­ro­pean coun­ter­part — backed by a who’s who of biotech in­vestors like For­bion, Or­biMed and Ver­sant  — for $17 per share, which is an 80% pre­mi­um to the pre­vi­ous 90-day vol­ume-weight­ed av­er­age. The agree­ment was en­tered in­to on Sun­day fol­low­ing board ap­proval from both sides.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER